AR052880A1 - Metodo para tratar dolor visceral - Google Patents
Metodo para tratar dolor visceralInfo
- Publication number
- AR052880A1 AR052880A1 ARP060100177A ARP060100177A AR052880A1 AR 052880 A1 AR052880 A1 AR 052880A1 AR P060100177 A ARP060100177 A AR P060100177A AR P060100177 A ARP060100177 A AR P060100177A AR 052880 A1 AR052880 A1 AR 052880A1
- Authority
- AR
- Argentina
- Prior art keywords
- visceral pain
- treat visceral
- administering
- oxycodone
- dose
- Prior art date
Links
- 208000009935 visceral pain Diseases 0.000 title abstract 4
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 abstract 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract 2
- 229960002085 oxycodone Drugs 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 229960005181 morphine Drugs 0.000 abstract 1
- 229940051877 other opioids in atc Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64549005P | 2005-01-18 | 2005-01-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR052880A1 true AR052880A1 (es) | 2007-04-11 |
Family
ID=35871217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100177A AR052880A1 (es) | 2005-01-18 | 2006-01-18 | Metodo para tratar dolor visceral |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20080200493A1 (enExample) |
| EP (1) | EP1838318B1 (enExample) |
| JP (1) | JP5049139B2 (enExample) |
| KR (10) | KR20190135557A (enExample) |
| CN (1) | CN101106996B (enExample) |
| AP (1) | AP2249A (enExample) |
| AR (1) | AR052880A1 (enExample) |
| AT (2) | ATE446092T1 (enExample) |
| AU (1) | AU2006207498B2 (enExample) |
| BR (1) | BRPI0606247A2 (enExample) |
| CA (1) | CA2595043C (enExample) |
| CY (1) | CY1109660T1 (enExample) |
| DE (2) | DE602006009899D1 (enExample) |
| DK (2) | DK1838318T3 (enExample) |
| EA (1) | EA013544B1 (enExample) |
| ES (1) | ES2333901T3 (enExample) |
| HR (1) | HRP20090679T1 (enExample) |
| IL (1) | IL184530A (enExample) |
| ME (1) | ME01066B (enExample) |
| MX (1) | MX2007007207A (enExample) |
| MY (1) | MY144471A (enExample) |
| NO (1) | NO338968B1 (enExample) |
| NZ (1) | NZ555852A (enExample) |
| PL (1) | PL1838318T3 (enExample) |
| PT (1) | PT1838318E (enExample) |
| RS (1) | RS51069B (enExample) |
| SI (1) | SI1838318T1 (enExample) |
| TW (1) | TWI432196B (enExample) |
| UA (1) | UA85471C2 (enExample) |
| WO (1) | WO2006077212A1 (enExample) |
| ZA (1) | ZA200705231B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3045182T1 (en) | 2005-11-14 | 2018-08-31 | Teva Pharmaceuticals International Gmbh | An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates |
| US8821928B2 (en) | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
| KR101304150B1 (ko) | 2008-03-04 | 2013-09-05 | 라브리스 바이올로직스 인코포레이티드 | 만성 통증의 치료 방법 |
| NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
| AU2010265213B2 (en) | 2009-06-24 | 2012-08-23 | Egalet Ltd. | Controlled release formulations |
| BR112012004464B8 (pt) * | 2009-08-28 | 2021-05-25 | Labrys Biologics Inc | uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica |
| CN108014334B (zh) | 2011-05-20 | 2021-11-30 | H.伦德贝克公司 | 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途 |
| PT3495392T (pt) | 2011-05-20 | 2021-09-22 | H Lundbeck As | Composições anti-cgrp e a sua utilização |
| EA033109B1 (ru) | 2011-05-20 | 2019-08-30 | Олдербайо Холдингз Ллк | Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| MX378344B (es) | 2014-03-21 | 2025-03-10 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. |
| SMT202600087T1 (it) | 2016-09-23 | 2026-03-09 | Teva Pharmaceuticals Int Gmbh | Trattamento dell’emicrania refrattaria |
| BR112021006027A2 (pt) | 2018-11-19 | 2021-06-29 | Jazz Pharmaceuticals Ireland Limited | formulações de fármaco resistente a álcool |
| CR20210373A (es) | 2019-01-08 | 2021-08-19 | H Lundbeck As | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp |
| GEAP202515803A (en) | 2019-05-02 | 2025-06-10 | H Lundbeck As | Treatment of headache using anti-cgrp antibodies |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656295A (en) * | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
| US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
| IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| PL187926B1 (pl) * | 1996-03-25 | 2004-11-30 | Lilly Co Eli | Kompozycja farmaceutyczna do leczenia bólu |
| UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
| US6992193B2 (en) * | 2003-06-10 | 2006-01-31 | Adolor Corporation | Sulfonylamino phenylacetamide derivatives and methods of their use |
-
2006
- 2006-01-05 TW TW095100458A patent/TWI432196B/zh not_active IP Right Cessation
- 2006-01-09 MY MYPI20060082A patent/MY144471A/en unknown
- 2006-01-17 NZ NZ555852A patent/NZ555852A/en unknown
- 2006-01-17 DE DE602006009899T patent/DE602006009899D1/de not_active Expired - Lifetime
- 2006-01-17 BR BRPI0606247-4A patent/BRPI0606247A2/pt not_active Application Discontinuation
- 2006-01-17 ME MEP-2009-352A patent/ME01066B/me unknown
- 2006-01-17 KR KR1020197035201A patent/KR20190135557A/ko not_active Ceased
- 2006-01-17 AU AU2006207498A patent/AU2006207498B2/en not_active Expired
- 2006-01-17 CN CN2006800024739A patent/CN101106996B/zh not_active Expired - Lifetime
- 2006-01-17 UA UAA200708142A patent/UA85471C2/ru unknown
- 2006-01-17 AT AT06700652T patent/ATE446092T1/de active
- 2006-01-17 DE DE202006019887U patent/DE202006019887U1/de not_active Expired - Lifetime
- 2006-01-17 CA CA2595043A patent/CA2595043C/en not_active Expired - Lifetime
- 2006-01-17 KR KR1020227041445A patent/KR20220165797A/ko not_active Ceased
- 2006-01-17 JP JP2007550797A patent/JP5049139B2/ja not_active Expired - Fee Related
- 2006-01-17 MX MX2007007207A patent/MX2007007207A/es active IP Right Grant
- 2006-01-17 US US11/814,020 patent/US20080200493A1/en not_active Abandoned
- 2006-01-17 PL PL06700652T patent/PL1838318T3/pl unknown
- 2006-01-17 EA EA200701541A patent/EA013544B1/ru not_active IP Right Cessation
- 2006-01-17 AP AP2007004057A patent/AP2249A/xx active
- 2006-01-17 KR KR1020087029312A patent/KR20080106991A/ko not_active Ceased
- 2006-01-17 KR KR1020237042001A patent/KR20230170811A/ko not_active Ceased
- 2006-01-17 ES ES06700652T patent/ES2333901T3/es not_active Expired - Lifetime
- 2006-01-17 KR KR1020177004572A patent/KR20170021905A/ko not_active Ceased
- 2006-01-17 SI SI200630538T patent/SI1838318T1/sl unknown
- 2006-01-17 KR KR1020077018905A patent/KR20070100368A/ko not_active Ceased
- 2006-01-17 HR HR20090679T patent/HRP20090679T1/hr unknown
- 2006-01-17 KR KR1020217034339A patent/KR20210131450A/ko not_active Ceased
- 2006-01-17 WO PCT/EP2006/050252 patent/WO2006077212A1/en not_active Ceased
- 2006-01-17 PT PT06700652T patent/PT1838318E/pt unknown
- 2006-01-17 KR KR1020127011713A patent/KR20120089710A/ko not_active Ceased
- 2006-01-17 EP EP06700652A patent/EP1838318B1/en not_active Expired - Lifetime
- 2006-01-17 KR KR1020207031796A patent/KR20200128451A/ko not_active Ceased
- 2006-01-17 DK DK06700652T patent/DK1838318T3/da active
- 2006-01-17 RS RSP-2009/0553A patent/RS51069B/sr unknown
- 2006-01-17 KR KR1020147018838A patent/KR20140091782A/ko not_active Ceased
- 2006-01-18 AR ARP060100177A patent/AR052880A1/es unknown
-
2007
- 2007-03-09 AT AT0014807U patent/AT9895U1/de not_active IP Right Cessation
- 2007-07-02 ZA ZA200705231A patent/ZA200705231B/xx unknown
- 2007-07-10 IL IL184530A patent/IL184530A/en active IP Right Grant
- 2007-07-24 DK DK200700207U patent/DK200700207U3/da not_active IP Right Cessation
- 2007-08-14 NO NO20074174A patent/NO338968B1/no not_active IP Right Cessation
-
2009
- 2009-12-16 CY CY20091101308T patent/CY1109660T1/el unknown
-
2014
- 2014-10-15 US US14/515,216 patent/US9271974B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20074174L (no) | Anvendelse av oksykodon for behandling av visceral smerte | |
| MX354249B (es) | Formas de dosificación farmacéuticas intranasales que comprenden naloxona. | |
| HRP20180436T1 (hr) | Upotreba amisulprida u liječenju mučnine i povraćanja uzrokovanih opijatima | |
| EA200802412A1 (ru) | Терапевтические комбинации для сопровождающихся болью медицинских состояний | |
| JO2858B1 (en) | Pharmaceutical dosage images | |
| AR058598A1 (es) | Administracion transdermica de meptazinol | |
| CL2008000606A1 (es) | Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y naloxona, util para el tratamiento del dolor. | |
| AR124500A2 (es) | Aumento de la biodisponibilidad de droga en terapia naltrexona | |
| UA109781C2 (uk) | Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них | |
| CL2011002858A1 (es) | Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor. | |
| AR092820A1 (es) | Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit | |
| EA201690276A1 (ru) | Комбинированная терапия с применением пептид эпоксикетонов | |
| CL2008000608A1 (es) | Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y naltrexona, util para el tratamiento del dolor. | |
| CO6382133A2 (es) | Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional | |
| MX2016007370A (es) | Agente terapeutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor. | |
| MX2009005798A (es) | Recuperacion de apoplejia. | |
| MX2020007860A (es) | Tratamientos combinados para crisis de opioides. | |
| EA200870182A1 (ru) | Применение комбинации морфина и по меньшей мере одного антагониста опиатов для лечения зависимости от опиатов для предотвращения непероральной опиатомании у наркоманов | |
| WO2011109743A3 (en) | Synergistic effects of combinations of buprenorphine and opioids for the treatment of pain | |
| GEP20125526B (en) | Drug active in neuropathic pain | |
| DE602004030048D1 (de) | Ffizienz | |
| WO2009019693A3 (en) | Analgesic effect of jasmonate derivatives | |
| EA201200319A1 (ru) | Введение активированного угля при оказании неотложной помощи в случае передозировки этексилата дабигатрана | |
| AR060394A1 (es) | Composicion farmaceutica que comprende un analgesico y vitaminas | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |